Angiogenesis and tumour proliferation in hepatocellular carcinoma after trans-arterial therapy
Phase 3
Not yet recruiting
- Conditions
- Hepatocellular carcinoma
- Registration Number
- SLCTR/2016/023
- Lead Sponsor
- Department of Surgery, Faculty of Medicine, University of Kelaniya
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Patients diagnosed with resectable hepatocellular carcinoma (tumour less than 5cm as determined by contrast enhanced CT scan) indicated for surgery
Exclusion Criteria
1. Portal vein and hepatic vein invasion needing urgent intervention
2. Allergy to contrast material or doxorubicin
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie angiogenesis inhibition post-trans-arterial chemo embolization in hepatocellular carcinoma?
How does trans-arterial chemo embolization compare to sorafenib in managing advanced hepatocellular carcinoma?
Which biomarkers correlate with tumour proliferation suppression after trans-arterial therapy in HCC patients?
What are the common adverse events associated with trans-arterial chemo embolization for liver cancer and their management?
Are there synergistic effects of combining trans-arterial chemo embolization with anti-VEGF therapies in hepatocellular carcinoma?